Naloxone Mini-Grant Program
For naloxone requests, please contact:
State Opioid Coordinator
Idaho Department of Health & Welfare
State Opioid Treatment Authority
Division of Behavioral Health
Naloxone is an opioid antagonist used to rapidly reverse the effects of opioid overdoses. The purpose of this program is to reduce the incidence of morbidity and mortality related to opioid overdoses in Idaho communities by getting this life-saving drug into the hands of those who are in a position to assist a person at risk of experiencing an opioid-related overdose.
Naloxone is not currently available over-the-counter. However, Idaho’s law allows pharmacists and other health professionals to prescribe and dispense to anyone at risk for an opioid-related overdose or to anyone who may encounter an such an individual. The Office of Drug Policy has a standing order to obtain naloxone on behalf of eligible agencies. These agencies will then be equipped to administer naloxone and keep an overdose patient alive until they can be transported to an emergency department. The agencies may also distribute the naloxone to individuals at risk of overdose, as well as their friends and family.
ODP has received grant funding for the purchase and distribution of naloxone kits to first responders and eligible agencies, prioritizing areas of Idaho with the highest overdose death rates as well as the highest number of overdose deaths.
Agencies eligible under this mini-grant program are:
- First Responders: Law Enforcement, Fire, and EMS
- Substance Use Disorder Treatment and Recovery Support Agencies
- Crisis Centers
- Homeless Shelters
- Hospital Emergency Departments
Agencies may store or have employees carry naloxone with the intent to administer to any individual they encounter who is experiencing an opioid overdose. Agencies may also distribute naloxone to clients, patients, and individuals being released from correctional facilities who are at risk of an overdose, as well as their friends and family.
Each naloxone kit contains 2 doses of 4mg Naloxone Nasal Spray. Agencies that receive naloxone through this mini-grant program will be asked to provide brief, online, quarterly reports.
FAQ Shelf Life Extension and Updated Storage Conditions – September 28, 2020
Quarterly reporting form: Naloxone Quarterly Reporting Form
Naloxone Nasal Spray Administration Instructional Video:
Program Outcome Reports
(Based on naloxone provided with State Opioid Response funding from IDHW Division of Behavioral Health ONLY)